Press release

Heerlen, NL, 13 Jan 2011 08:15 CET

Royal DSM N.V. (NYSE Euronext: DSM KON), the global Life Sciences and Materials Sciences company headquartered in the Netherlands, today announces that its indirect wholly-owned subsidiary, Greenback Acquisition Corporation, has commenced its tender offer for all outstanding shares of common stock of Martek Biosciences Corporation (NASDAQ: MATK) at a price of $31.50 per share.

The tender offer is being made in connection with the Agreement and Plan of Merger, dated as of 20 December 2010, by and among DSM, Greenback Acquisition Corporation and Martek, which DSM and Martek announced on 21 December 2010.

The Martek board of directors has unanimously determined that, among other things, the offer is fair to and in the best interests of Martek’s stockholders and unanimously recommends that Martek’s stockholders accept the offer and tender their shares.

The tender offer is scheduled to expire at 5:00 p.m. (New York City time) on Friday, 18 February 2011, unless the offer is extended.

Complete terms and conditions of the tender offer are set forth in the Offer to Purchase, Letter of Transmittal and other related materials that will be filed by DSM and Greenback Acquisition Corporation with the SEC on 13 January 2011. In addition, on 13 January 2011, Martek will file a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC relating to the offer. Copies of the Offer to Purchase, Letter of Transmittal and other related materials are available free of charge from MacKenzie Partners, Inc., the information agent for the tender offer, toll-free at (800) 322-2885. The dealer manager for the tender offer is J.P. Morgan Securities LLC. Citibank, N.A. is acting as depositary for the tender offer.

Martek

Martek is a leader in the innovation, development, production and sale of high-value products from microbial sources that promote health and wellness through nutrition. Martek’s technology platform consists of its core expertise, broad experience and proprietary technology in areas such as microbial biology, algal genomics, fermentation and downstream processing. This technology platform has resulted in Martek’s development of a number of products, including the company’s flagship product, life’sDHA™, a sustainable and vegetarian source of algal DHA (docosahexaenoic acid) important for brain, heart and eye health throughout life for use in infant formula, pregnancy and nursing products, foods and beverages, dietary supplements and animal feeds. Martek also produces life’sARA™ (arachidonic acid), an omega-6 fatty acid, for use in infant formula and follow-on formulas. Martek’s subsidiary, Amerifit Brands, develops, markets and distributes branded consumer health and wellness products and holds leading brand positions in all of its key product categories. Amerifit products are sold in most major mass, club, drug, grocery and specialty stores and include: Culturelle® a leading probiotic supplement; AZO, the leading OTC brand addressing symptom relief and detection of urinary tract infections; and Estroven®, the leading all-natural nutritional supplement brand addressing the symptoms of menopause.